Insights from the ASCO Genitourinary Cancers Symposium

Videos

Using Intermediate Endpoints to Evaluate the Efficacy of ICIs for Treating Metastatic Renal Cell Carcinoma

03/22/2024

Featuring Renée Saliby, MD

Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.

Renée Saliby, MD, summarizes her...

03/22/2024

Journal of Clinical Pathways

Videos

The Potential of Enfortumab Vedotin After Maintenance Avelumab For Treating Patients With Advanced Urothelial Carcinoma: The UNITE Study

03/04/2024

Featuring Amanda Nizam, MD

Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.

Amanda Nizam, MD, discusses the...

03/04/2024

Journal of Clinical Pathways

Videos

Defining the Features of Urothelial Carcinoma at ASCO GU 2024

02/21/2024

Featuring Syed Muneeb Alam, MD

Featuring Syed Muneeb Alam, MD ...

Syed Muneeb Alam, MD, from Memorial Sloan Kettering Cancer Center, shares some details about the abstract he presented at ASCO GU 2024 on the definition, diagnosis, and new technologies available for physicians treating patients with...

Syed Muneeb Alam, MD, from...

02/21/2024

Journal of Clinical Pathways

Videos

Highlights and Key Takeaways in Prostate Cancer From ASCO GU 2024

02/15/2024

Featuring Alexandra Sokolova, MD

Featuring Alexandra Sokolova, MD ...

Alexandra Sokolova, MD, shares her thoughts on the most compelling research in prostate cancer presented at the 2024 ASCO Genitourinary Cancers Symposium.

Alexandra Sokolova, MD, shares...

02/15/2024

Journal of Clinical Pathways

News

Treatment Patterns and Overall Survival for Patients With Metastatic Urothelial Carcinoma Following FDA Approval of Avelumab Maintenance Therapy

02/15/2024

Grace Taylor

A study by Haojie Li, MD, PhD, and colleagues evaluated real-world treatment patterns and overall survival for patients with mUC during the period between the approval of maintA and P+EV for use in the US.

A study by Haojie Li, MD, PhD,...

02/15/2024

Journal of Clinical Pathways

Videos

KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell Renal Cell Carcinoma

01/27/2024

Featuring Toni Choueiri, MD

Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.

Toni Choueiri, MD, gives a...

01/27/2024

Journal of Clinical Pathways

Videos

Outcomes of Men With High-Risk, Biochemically Recurrent Prostate Cancer Who Discontinued Enzalutamide Monotherapy in the EMBARK Study

01/18/2024

Featuring Neal Shore, MD, FACS

Featuring Neal Shore, MD, FACS ...

Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.

Neal Shore, MD, FACS, discusses...

01/18/2024

Journal of Clinical Pathways

Videos

Costs of Adverse Event Management for Patients with Metastatic Renal Cell Carcinoma Treated With a VEGFR TKI

05/25/2023

Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.

Jeff Yorio, MD, Texas Oncology,...

05/25/2023

Journal of Clinical Pathways

Conference Coverage

Outcomes and Costs of Treatment for Patients With Metastatic Upper Tract Urothelial Carcinoma

03/31/2023

Grace Taylor

At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).

At the 2023 ASCO GU Cancers...

03/31/2023

Journal of Clinical Pathways

News

Study Analyzes Cabozantinib Plus Nivolumab and Ipilimumab for Patients With aRCC Who Have IMDC Intermediate or Poor Risk Scores

03/30/2023

Grace Taylor

At the 2023 ASCO GU Cancers Symposium, Thomas Powles, MD, and colleagues presented an analysis of the phase 3 clinical trial COSMIC-313, which compared the use of cabozantinib (C) plus nivolumab (N) and ipilimumab (I) versus a placebo with N...

At the 2023 ASCO GU Cancers...

03/30/2023

Journal of Clinical Pathways

Videos

Analyzing the Cost-Effectiveness of Treatment Regimens in Metastatic Hormone-Sensitive Prostate Cancer

03/10/2023

Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.

Manish Kohli, MD, compared the...

03/10/2023

Journal of Clinical Pathways

Videos

Clinical Outcomes With Early vs Late Ra-223 for Patients With Metastatic CRPC

04/23/2021

Richard Lee-Ying, MD, discusses clinical outcomes of patients with metastatic castrate resistant prostate cancer when Ra-223 is used early vs late in the treatment sequence.

Richard Lee-Ying, MD, discusses...

04/23/2021

Journal of Clinical Pathways

Videos

Real-World Use of Cabozantinib Plus Direct Oral Anticoagulants in RCC

04/21/2021

Journal of Clinical Pathways

Videos

Enfortumab Vedotin vs Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma

03/23/2021

Journal of Clinical Pathways

Insights From ASCO 2021

Prescribing Patterns in Metastatic Castrate-Sensitive Prostate Cancer

03/23/2021

Nataliya Mar, MD, UC Irvine Medical Center, Orange, CA, discusses results from a study exploring prescribing among patients with metastatic castrate-sensitive prostate cancer (CSPC). These results were presented at the virtual 2021 ASCO...

Nataliya Mar, MD, UC Irvine...

03/23/2021

Journal of Clinical Pathways

Videos

Patterns and Predictors of Oral Anticancer Agent Use for Metastatic RCC

03/18/2021

Journal of Clinical Pathways

Videos

Treatment Patterns After PD1/L1 Inhibitor Discontinuation in Advanced Urothelial Carcinoma

03/18/2021

Journal of Clinical Pathways

Videos

Real-World Treatment Sequences After First-Line Therapy in Metastatic RCC

03/18/2021

Journal of Clinical Pathways

Videos

Higher Hospital Competition Associated With Improved Quality of Prostate Cancer Care

03/18/2021

Journal of Clinical Pathways

Videos

Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma

03/12/2021

Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.

Nimira Alimohamed, MD, discusses...

03/12/2021

Journal of Clinical Pathways

Conference Coverage

Advanced Oral Therapy Adherence Among Patients With Prostate Cancer

03/03/2021

Journal of Clinical Pathways

Videos

Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer

02/25/2021

Journal of Clinical Pathways

Videos

Impact of Oral Anticancer Agent Adherence on Survival Outcomes in Metastatic RCC

02/25/2021

Journal of Clinical Pathways

Videos

Hospital Efficiency Impact on Quality of Prostate Cancer Care

02/24/2021

Journal of Clinical Pathways

Videos

Provider Preferences for Prostate Cancer: Medical Oncologists vs Urologists

02/21/2021

Journal of Clinical Pathways

Conference Coverage

Apalutamide Plus ADT Improves OS in Metastatic Castration-Sensitive Prostate Cancer

02/21/2021

Journal of Clinical Pathways

Videos

Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma

02/19/2021

Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.

Shilpa Gupta, MD, discusses the...

02/19/2021

Journal of Clinical Pathways